HAYA Therapeutics Raises $65 Million in Series A Funding to Deliver Precision RNA-Guided Medicines for Chronic and Age-Related Diseases
Series A round led by Sofinnova Partners and Earlybird Venture Capital with syndicate including Eli Lilly and Company Funds to advance clinical development of heart failure lead candidate and expand platform targeting the regulatory genome…